Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients: A Hellenic Cooperative Oncology Group Study

Gynecologic Oncology

Volumn 92, Issue 1, 2004, Pages 152-159

  Papadimitriou, Christos A ^a   Fountzilas, George ^b   Aravantinos, Gerassimos ^c   Kalofonos, Charalambos ^d   Moulopoulos, Lia A ^e   Briassoulis, Evangelos ^f   Gika, Dimitra ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

^f UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Carboplatin; Gemcitabine; Platinum sensitive relapsed ovarian cancer; Second line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; IFOSFAMIDE; NUCLEOSIDE DERIVATIVE; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HEART ARREST; HUMAN; INFECTION; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; OVARY TUMOR; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0742289996     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.09.021     Document Type: Article

References (60)

1. Ozols R.F., Rubin S.C., Thomas G., Robboy S. Epithelial ovarian cancer. Huskins W.M., Perez C.A., Young R.C. Principles and practice of gynecologic oncology. Second ed. 1997;919-986 Lippincott-Raven Publishers, Philadelphia.
2. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Patridge E.E., Look K.Y.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
3. Neijt J.P. New therapy for ovarian cancer. N. Engl. J. Med. 334:1996;50-51.
4. Du Bois A., Neijt J.P., Thigpen J.T. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - A new standard of care? Ann. Oncol. 10(Suppl. 1):1999;S35-S41.
5. Ozols R.F., Bundy B.N., Fowler J., Clarke-Pearson D., Mannel R., Hartenbach E.et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158) [abstract 1373]. Proc. Am. Soc. Clin. Oncol. 18:1999;356a.
6. Du Bois A., Lueck H.J., Meier W., Moebus V., Costas D., Bauknecht T.et al. Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial [abstract 1374]. Proc. Am. Soc. Clin. Oncol. 18:1999;356a.
7. Aravantinos G., Fountzilas G., Kosmidis P., Dimopoulos M.A., Stathopoulos G., Pavlidis N.et al. Alternating carboplatin and cisplatin plus paclitaxel versus carboplatin plus paclitaxel for first line treatment of advanced ovarian cancer (AOC): updated results of a phase III Hellenic Cooperative Oncology Group Study [abstract 1538]. Proc. Am. Soc. Clin. Oncol. 19:2000;389a.
8. Goldberg J.M., Piver M.S., Hempling R.H., Recio F.O. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol. Oncol. 63:1996;312-317.
9. Ozols R.F. Treatment of recurrent ovarian cancer: increasing option-'recurrent' results. J. Clin. Oncol. 15:1997;2177-2180.
10. Ozols R.F. Update on the NCCD Ovarian Cancer Practice Guidelines. Oncology. 11(A):1997;95-105.
11. Rose P.G., Fusco N., Fluellen L., Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. 16:1998;1494-1497.
12. Guastalla J.P., Pujada-Lauraine E., Weber B., Cure H., Orfeuvre H., Mousseau M.et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study. Ann. Oncol. 9:1998;37-43.
13. Sabbatini P., Sprongs D. Salvage therapy for ovarian cancer. Oncology. 12:1998;833-844.
14. Miller A.B., Hogestraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
15. Hryniuk K.W.M., Goodyear M. The calculation of received dose intensity. J. Clin. Oncol. 8:1990;1935-1937.
16. Kaplan E., Meier F. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 58:1958;457-481.
17. Markman M., Hoskins W. Response to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated populations. J. Clin. Oncol. 10:1992;513-514.
18. Eisenhauer E.A., Swenerton K.D., Sturgeon F.G., Fine S., O'Reilly S.E. Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Trials Group Study. Cancer Treat. Rep. 70:1986;1195-1198.
19. Canetta R., Bragman K., Smaldone L., Rosencweig M. Carboplatin: current status and future prospects. Cancer Treat. Rev. 15:1988;17-32.
20. Gore M.E., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36:1990;207-211.
21. Williams L.L., Fudge M., Burnett L.S., Jones H.W. Salvage carboplatin therapy for advanced ovarian cancer after first-line treatment with cisplatin. Am. J. Clin. Oncol. 15:1992;331-336.
22. Gershenson D.M., Kavanagh J.J., Copeland L.J., Stringer C.A., Morris M., Wharton J.T. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet. Gynecol. 73:1989;798-802.
23. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S.et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9:1991;389-393.
24. Beker J.S., Bertelsen K., du Bois A.et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann. Oncol. 10(Suppl. 1):1999;587-592.
25. Dizon D., Hensley M., Sabbatini P., Poynor E., Hummer A., Venkatraman E.et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma. J. Clin. Oncol. 20:2002;1238-1247.
26. Van der Burg M.E., Hoff A.M., Van Lent M., Rodenburg C.J., van Puttten W.L., Stoter G. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur. J. Cancer. 27:1991;248-250.
27. Martoni A., Panetta A., Angelleli B., Melotti B., Pannuti F. A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma. J. Chemother. 5:1993;47-51.
28. Lorusso V., Catino A., Leone B., Rabinovich M., Gargano G., Paradiso A. et al. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J. Clin. Oncol. 11:1993;1952-1956.
29. Hertel L.W., Kroin J.S., Misner J.W.et al. Synthesis of 2-deoxy-2′,2′-difluoro-D-ribose and 2-deoxy-2′,2′- difluoro-D-ribofuranosyl nucleosides. J. Org. Chem. 53:1988;2406-2409.
30. Hertel L.W., Boder G.B., Kroin J.S., Rinzel S.M., Poore G.A., Todd G.C. et al. Evaluation of the antitumor activity of 2′,2′-difluoro- 2′-deoxy-cytidine. Cancer Res. 50:1990;4417-4422.
31. Braakhuis B.J., van Dongen G.A.M.S., Vermorken J.B., Snow G.B. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against head and neck cancer. Cancer Res. 51:1991;211-214.
32. Lund B., Kristyansen P.E.G., Hansen H. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat. Rev. 19:1993;45-55.
33. Boven E., Schipper H., Erkelens C.A.M.et al. The influence of the schedule and the dose of gemcitabine on the antitumor efficacy in experimental human cancer. Br. J. Cancer. 68:1993;52-56.
34. Peters G.J., Ackland S.P. New antimetabolites in preclinical and clinical development. Exp. Opin. Invest. Drugs. 5:1996;637-679.
35. Lund B., Hansen O.P., Theilade K., Hansen M., Neijt J.P. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J. Natl. Cancer Inst. 86:1994;1530-1533.
36. Neijt J.P., Kaufmann M., Bauknecht T.et al. Gemcitabine in pretreated ovarian cancer [abstract 329]. Ann. Oncol. 7(Suppl. 5):1996;70.
37. Friedlander M., Millward M.J., Bell D., Bugat R., Harnett P., Moreno J.A.et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann. Oncol. 9:1998;1343-1345.
38. von Minckwitz G., Bauknecht T., Visseren-Grul C.M., Neijt J.P. Phase II study of gemcitabine in ovarian cancer. Ann. Oncol. 10:1999;853-855.
39. Shapiro J.D., Millward M.J., Rischin D.et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 63:1996;89-93.
40. Markman M., Kennedy A., Webster K., Zanotti K., Kulp B., Peterson G.et al. Phase 2 trial of single-agent gemcitabine (GEM) in platinum (PLAT)/paclitaxel (PAC) refractory ovarian cancer (ROC) [abstract 813]. Proc. Am. Soc. Clin. Oncol. 20:2001;204a.
41. Kudelka A.P., Vershraegen C.F., Edwards C.L., Freedman R., Plunkett W., Stev N.et al. A preliminary report of a phase 2 study of gemcitabine in women with platinum refractory mullerian (ovarian, fallopian tube, and primary peritoneal) carcinomas [abstract 1357]. Proc. Am. Soc. Clin. Oncol. 18:1999;377a.
42. Kunkel L.M., Evans S.S., Dottino P.R., Di Saia P.J., Nagourney R.A. Cisplatin (CDDP) and gemcitabine (DEDC) in relapsed ovarian cancer [abstract 1379]. Proc. Am. Soc. Clin. Oncol. 17:1998;357a.
43. Orlando M., Nadal J., Chacon R.D. Gemcitabine (G) and carboplatin (C) in patients (Pts) with relapsed ovarian cancer (ROC): a phase I-II study [abstract 1594]. Proc. Am. Soc. Clin. Oncol. 19:2000;403a.
44. Du Bois A., Lueck H.J., Pfisterer J., Schroeder W., Blohmer J.U., Kimmig R.et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer. A dose finding study by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Ovarian Cancer Study Group. Ann. Oncol. 12:2001;1115-1120.
45. Velasco A., Perez M.M., Borrega P., Gomez-Bernal A., Arranz J.A., Gonzalez-Beca R. Gemcitabine (GEM) and cisplatin (CIS) as treatment for patients with platinum resistant ovarian cancer (OC) and as consolidation treatment for patients with residual disease after first line chemotherapy [abstract 2478]. Proc. Am. Soc. Clin. Oncol. 20:2001;182b.
46. Rose P.G., Mossbruger K., Fusco N., Smrekar M., Eaton S., Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum - and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol. Oncol. 88:2003;17-21.
47. Nagourney R.A., Brewer C.A., Radecki S., Kidder W.A., Sommers B.L., Evans S.S.et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol. Oncol. 88:2003;35-39.
48. Poole C.J., Perren T., Hogberg T., Cook J., Jenkins A.H., Ridderheim M. et al. Phase I study to investigate the optimal dose and schedule of gemcitabine (G) and paclitaxel (P) in combination in patients with previously treated epithelial ovarian cancer [abstract 1380]. Proc. Am. Soc. Clin. Oncol. 17:1998;357a.
49. Roman L., Garcia A.A., Facio G., Jeffers S., Santiago J., Munderspach L.et al. Phase II study of weekly paclitaxel and gemcitabine in platinum resistant ovarian cancer [abstract 877]. Proc. Am. Soc. Clin. Oncol. 20:2001;220a.
50. Jungnelius J.U., Ridderheim M., Perren T., Gawande S., Roychowdhury D., Poole C. Optimal sequence leads to improved dose delivery for gemcitabine (G)/paclitaxel (P) combination in recurrent ovarian cancer: a phase I study [abstract 890]. Proc. Am. Soc. Clin. Oncol. 21:2002;223a.
51. Geertsen P., Hansen M., Stroyer I., Hansen S. Combination chemotherapy with platinum paclitaxel, and gemcitabine in patients' with relapsed ovarian carcinoma [abstract 1395]. Proc. Am. Soc. Clin. Oncol. 18:1999;361a.
52. Gupta S., Arora R., John S., Nayak R., Vajpeyi R., Kilara G.et al. Gemcitabine, paclitaxel and cisplatin in chemotherapy naïve advanced ovarian cancer: results of a multicenter phase II study [abstract 857]. Proc. Am. Soc. Clin. Oncol. 21:2002;215a.
53. Hansen S.W., Anderson H., Boman K., Hansen M., Havsteen H., Rosenberg P.et al. Gemcitabine, carboplatin and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV [abstract 1379]. Proc. Am. Soc. Clin. Oncol. 18:1999;357a.
54. Belpomme D., Krakowsk I., Beauduin M., Petit T., Canon J.L., Janssens J.et al. Gemcitabine (G) combined with cisplatin (C) is active and feasible as first-line treatment in patients with advanced epithelial ovarian cancer (OC): final results of a phase II study [abstract 859]. Proc. Am. Soc. Clin. Oncol. 21:2002;215a.
55. Shaharyar, Shami N., Mahmood I., Alauddin Z., Mahmood A., Chaudhry K.M. et al. A phase II trial of gemcitabine and cisplatin combination chemotherapy in advanced epithelial ovarian cancer with bulky residual disease [abstract 2518]. Proc. Am. Soc. Clin. Oncol. 21:2002;175b.
56. Carmichael J., Allerheiligen S., Walling J. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin. Oncol. 23:1996;55-59.
57. Iaffaioli R.V., Tortoriello A., Facchini G.et al. Phase I-II study of gemcitabine and carboplatin in non-small-cell lung cancer. J. Clin. Oncol. 17:1999;921-926.
58. Edelman M.J., Gandara D.R., Lau D.H., Lara P., Lauder I.J., Tracy D. Sequential combination chemotherapy in patients with advanced non small cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer. 92:2001;146-152.
59. Van Moorsel C.J.A., Pinedo H.M., Veerman G.et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer. Br. J. Cancer. 80:1999;981-990.
60. Van Moorsel C.J.A., Pinedo H.M., Veerman G.et al. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur. J. Cancer. 35:1999;808-814.